The influence of duodenally-delivered Shakuyakukanzoto (Shao Yao Gan Cao Tang) on duodenal peristalsis during endoscopic retrograde cholangiopancreatography: a randomised controlled trial

Abstract Background Anti-cholinergic agents may be used to inhibit duodenal peristalsis, but they may have adverse effects. Shakuyakukanzoto ( Shao Yao Gan Cao Tang ) has an anti-spasmodic effect and has been used before for oesophagogastroduodenoscopy and colonoscopy. This randomised clinical trial aimed to evaluate the inhibitory effect of Shakuyakukanzoto on duodenal peristalsis, and its usefulness when administered into the duodenum just before endoscopic retrograde cholangiopancreatography (ERCP). Methods Participants were recruited between June 2008 and December 2010. All were aged\ua0\u226518\ua0years and provided written informed consent. Exclusion criteria were: acute pancreatitis, a history of ischemic heart disease, prostatic hypertrophy or glaucoma, and altered/postsurgical upper gastrointestinal anatomy. The recruited participants were randomly assigned to the Shakuyakukanzoto group and control group. Shakuyakukanzoto 100\ua0mg/mL solution or placebo (warm water) was administered directly as a spray into the duodenum during endoscopy. Efficacy was evaluated by observing the extent of duodenal peristalsis and assessing the difficulty of cannulating the common bile duct, the required time (RT) from administration to inhibition of duodenal peristalsis and the stop duration time (DT, the duration for which peristalsis was inhibited). Side effects were evaluated by measuring serum potassium concentration after ERCP. Results Of 28 participants, 15 were assigned to the Shakuyakukanzoto group and 13 to the control group. Duodenal peristalsis was inhibited in eight of the 10 eligible participants (80.0%) in the Shakuyakukanzoto group and none (0%) of the nine eligible participants in the control group ( P \ua0=\ua00.026). In the Shakuyakukanzoto group, mean RT (\ub1standard deviation) was 76.0\ua0\ub1\ua023.9\ua0s and DT was 11.3\ua0\ub1\ua04.2\ua0min. No adverse effects were observed in the Shakuyakukanzoto group during or after ERCP. Conclusion Duodenal peristalsis can be inhibited by spraying Shakuyakukanzoto solution directly into the duodenum. Trial registration UMIN Clinical Trials Registry (UMIN-CTR) UMIN00001146

A Review of Potential Role of Capsule Endoscopy in the Work-Up for Chemotherapy-Induced Diarrhea

Chemotherapy-induced diarrhea (CID) is a common, severe side effect of chemotherapy, immunotherapy, and targeted therapy. Because patients are more prone to continuing chemotherapy if they do not suffer from CID, appropriate diagnosis and monitoring of this disease are essential. However, suitable monitoring methods are yet to be developed. To date, several studies have shown that small-bowel capsule endoscopy (SBCE) is useful in visualizing the entire small intestinal mucosa and detecting small intestinal abnormalities, including bleeding, malignant tumors, and mucosal injury, associated with the use of nonsteroidal anti-inflammatory drugs and low-dose aspirin. Currently, limited studies have evaluated the small intestinal mucosa using SBCE in patients receiving fluoropyrimidine-based chemotherapy or immune checkpoint inhibitors. These studies have reported that small intestinal mucosal injury is common in patients with severe fluoropyrimidine-induced diarrhea. SBCE might be a useful screening method for the early detection of enterocolitis induced by immune checkpoint inhibitors. SBCE may be a powerful tool for the diagnosis and monitoring of CID, and understanding its indication, contraindication, and capsule-retention risk for each patient is important for clinicians

Assessment of a Hands-On Seminar on Gastrointestinal Ultrasound

Transabdominal gastrointestinal (GI) ultrasound (US), despite its utility, is not a common procedure and underappreciated owing to its difficulty to perform. This study aimed to disseminate the skills of GIUS and assess the impact of our hands-on seminar. We annually held a half-day, hands-on seminar on GIUS at University of Toyama Hospital for physicians and sonographers from 2015 to 2017. Two months after the seminar, we inquired about clinical attainment by questionnaire. Out of 55 participants, 46 (83.6%) returned their questionnaires. Twenty participants (43.5%) reported that they had successfully diagnosed at least one GI disorder via GIUS since the seminar. Residual analyses stratified by the participants’ background showed that the novices, those having < 2 years’ experience in performing abdominal US, or no prior knowledge of GIUS, had significantly lower attainment rates (23.5% and 12.5%, respectively) than the others. Participants with 2 to 5 years’ experience in performing abdominal US or with some knowledge of GIUS had much higher rates of diagnosing GI disorders (54.5% and 57.9%, respectively). Nearly half of the participants had identified GI disorders using GIUS in 2 months following the training. The hands-on seminar was beneficial in disseminating these skills among a wide range of US operators